Literature DB >> 17329141

Association of serum levels of IGF-I and IGFBP-1 with renal function in patients with type 2 diabetes mellitus.

Mujde Akturk1, Metin Arslan, Alev Altinova, Aysegul Ozdemir, Reyhan Ersoy, Ilhan Yetkin, Elif Ayvali, Sevim Gonen, Fusun Toruner.   

Abstract

OBJECTIVE: Our aim was to determine whether serum Insulin-like growth factor-I (IGF-I) and Insulin-like growth factor binding protein-1 (IGFBP-1) levels were different between type 2 diabetic patients and non-diabetic control group. We also aimed to establish any relationship that might exist between the serum IGF-I and IGFBP-1 levels with the urinary albumin excretion (UAE), creatinine clearance and urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion (as a marker of renal tubular dysfunction) and other parameters (such as age, duration of diabetes, treatment, etc.) in patients with type 2 diabetes mellitus (DM).
DESIGN: Fifty-nine type 2 diabetic patients and thirty-one non-diabetic controls were included in this study.
RESULTS: Mean serum IGF-I levels in diabetic patients were lower than the non-diabetic controls (158+/-12 vs. 287+/-26microg/l), (p<0.001). Serum IGFBP-1 levels were also higher in type 2 diabetic patients compared to the control group (67+/-5 vs. 35+/-4microg/l), (p<0.001). No relationship was obtained between IGF-I and IGFBP-1 levels with neither UAE nor urinary NAG excretion. A significant negative relationship was observed between creatinine clearance and serum IGFBP-1 level (r=-0.39, p=0.004). In multiple regression analysis IGF-I was independently and negatively associated with age and insulin treatment. On the other hand, IGFBP-1 was negatively related with creatinine clearance and positively related with the duration of diabetes.
CONCLUSION: These results suggest that type 2 DM leads to a decrease in the IGF-I while elevating the IGFBP-1 levels. Further studies are needed to clarify a potential role of increased levels of IGFBP-1 in decreased creatinine clearance in type 2 DM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329141     DOI: 10.1016/j.ghir.2007.01.007

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  5 in total

Review 1.  The Promise of Systems Biology for Diabetic Kidney Disease.

Authors:  Frank C Brosius; Wenjun Ju
Journal:  Adv Chronic Kidney Dis       Date:  2018-03       Impact factor: 3.620

2.  Increased Urine IgM and IgG(2) Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes.

Authors:  Ole Torffvit; Majid Kalani; Jan Apelqvist; Björn Eliasson; Jan W Eriksson; Kerstin Brismar; Gun Jörneskog
Journal:  Biochem Res Int       Date:  2012-02-12

Review 3.  Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases.

Authors:  Alexander O Shpakov; Kira V Derkach; Lev M Berstein
Journal:  Future Sci OA       Date:  2015-11-01

4.  Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma.

Authors:  Jinjin Yan; Xinzheng Yang; Lin Li; Pengtao Liu; Honghui Wu; Zhanao Liu; Qingyi Li; Guozhen Liao; Xinlong Wang
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

5.  Elevated expression levels of serum insulin-like growth factor-1, tumor necrosis factor-α and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy.

Authors:  Xiang Li; Ting-Ting Wu; Juan Chen; Wen Qiu
Journal:  J Diabetes Investig       Date:  2016-07-15       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.